MHY-1685 - Moligand™, 10 mM in DMSO , CAS No.27406-31-1

CAS: 27406-31-1 Cat. No.: M1496928 Formula: C₁₁H₈N₂O₄ Molecular Weight: 232.19 EC Number: 683-840-6 PubChem CID: 5292673

GRADE & PURITY Moligand™, 10 mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

MHY-1685, a novel mammalian target of rapamycin ( mTOR ) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.

Specifications

Specifications & Purity

Moligand™, 10 mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

INHIBITOR

Names and Identifiers

Isomeric SMILES

C1=CC(=CC=C1C=C2C(=O)NC(=O)NC2=O)O

PubChem CID

5292673

Molecular Weight

232.19

Application Protocols

No tested biological or analytical application protocols are provided for MHY-1685 in the Product Data.

• General handling protocol for screening use (non-validated template)
  • Stock solution: Dissolve compound in anhydrous DMSO to 10–50 mM. Vortex/sonicate as needed; warm gently (≤40 °C) if required. Record exact concentration.
  • Aliquoting: Dispense single-use aliquots (e.g., 10–50 µL) in low-bind tubes/plates. Store at −80 °C. Avoid repeated freeze–thaw cycles.
  • Working dilutions: Prepare serial dilutions in DMSO, then back-dilute into assay buffer to final DMSO 0.1–1% v/v, matching vehicle controls.
  • Quality checks: Inspect for precipitation/turbidity after dilution; if observed, adjust co-solvent fraction within assay constraints or reassess concentration range.
• Analytical QC (suggested, not item-specific)
  • Confirm identity/purity by LC–MS or UPLC prior to critical experiments. Re-verify after prolonged storage.

For any target- or assay-specific procedures (WB, IHC, IF, enzymology), no recommendations are provided—develop and validate according to your platform’s SOPs.

Biological Roles

• Item-specific biological function/targets
  • Not specified for this item; no target class, pathway, or mode of action is provided in the Product Data. The compound is supplied strictly for research use only.
• General considerations for screening ligands (non-clinical)
  • In early discovery, compounds like MHY-1685 may be profiled across biochemical, biophysical, or cell-free systems to explore binding or activity. Where target specificity is unknown, broad-panel counterscreens can de-risk false positives (e.g., aggregation, redox cycling, fluorescence interference).
  • For biophysical characterization, techniques such as differential scanning fluorimetry (DSF), microscale thermophoresis (MST), SPR, or NMR may be used to assess interactions. Assay selection should be guided by the eventual target class if identified.
• ADME/tox inference
  • No ADME or toxicity information is provided. Do not infer any pharmacological, toxicological, or clinical properties from the presence of this item in a screening collection.

Note: Aladdin Scientific makes no medical or clinical claims for this item. All uses are restricted to research in appropriate laboratory environments.

Buffer Applications

This product is a small-molecule screening compound, not a buffering agent.

• Applicability
  • Not typically used to prepare buffers or to control pH. No pKa or buffering range is provided.
• Practical note
  • When dosing into biochemical buffers, ensure vehicle controls match the final co-solvent content (e.g., DMSO 0.1–1% v/v). Verify precipitation risk upon dilution and adjust ionic strength or co-solvent fraction within assay limits as needed.

Green Alternatives

For Moligand™ screening compounds, the main environmental considerations arise from solvent choice and plate-washing workflows rather than the compound itself (structure-specific hazards are not provided).

• Greener solvent strategies (general guidance)
  • Prefer aqueous buffer with minimal DMSO where solubility permits; target ≤0.1–0.5% v/v DMSO in assay wells.
  • If organic cosolvent is needed at preparation stage, DMSO is generally safer and less volatile than DMF/NMP; however, evaluate ethanol or isopropanol for reduced persistence and easier waste processing if compatible with your assay.
• Comparison (general; not item-specific)
  • DMSO: Low volatility, broad solubility, good lab safety profile; may enhance dermal uptake—use gloves.
  • Ethanol: Renewable feedstocks available; more volatile; narrower solubility envelope.
  • 2-MeTHF/CPME: Greener ethers for synthetic chemistry; rarely needed for screening stocks and often incompatible with aqueous assays.
• Operational reductions
  • Minimize single-use plastics by employing solvent-compatible, reusable glassware for stock preparation when feasible.
  • Consolidate waste streams (e.g., segregate halogen-free organics) to enable energy-efficient disposal.
• Data gaps
  • Without structure and hazard classification, compound-specific green metrics (biodegradability, aquatic toxicity, PMI effects) cannot be provided. Treat this item as “data-limited” and manage principally through solvent, scale, and exposure controls.

Pharmaceutical Uses

• Regulatory/compendial status
  • Not specified for this item; no pharmacopeial monograph or excipient designation is provided.
• Intended use
  • Supplied for research use only. Not for human or veterinary use, diagnostics, or clinical applications.
• Formulation context (general research note)
  • In discovery, small molecules may be formulated into DMSO stocks and further diluted into assay media. Any discussion of dosage forms or therapeutic applications is out of scope for this product.

If you require GMP-suitable material or documentation aligned to clinical development, please contact us for alternative sourcing. This Moligand™ SKU is not intended for such use.

Physical Properties

• Item-specific properties (Product Data)
  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Storage (Product Data)
  • Store at −80 °C. Shipped on dry ice packs + cold packs to maintain frozen integrity.
• Typical screening-compound handling (general guidance; not item-specific specs)
  • Solubility: Many library members are supplied neat or as dry films suited to dissolution in anhydrous DMSO to prepare 10–50 mM stocks. Actual solubility for MHY-1685 is not specified; verify empirically at small scale.
  • Hygroscopicity: Unknown for this item; minimize ambient exposure to prevent water uptake if the compound is moisture sensitive.
  • pKa/logP: Not specified for this item; refer to CoA/Spec Sheet or compute from structure where available.
  • MP/BP, density, refractive index: Not specified for this item; refer to CoA/Spec Sheet.
• Practical recommendations (general)
  • Thaw-on-ice and keep solutions cold while aliquoting to reduce freeze–thaw cycles.
  • For aqueous work, consider co-solvent strategies (e.g., DMSO to 0.1–1% v/v final) and surfactant-free conditions unless your assay supports them.
  • Filter solutions (0.2 µm PTFE) only if compatible; avoid adsorption losses by pre-wetting filters with solvent.

All definitive physicochemical numbers should be taken from the item’s CoA/SDS; do not treat the above general guidance as specifications.

Quality & Grades

• Supplied grade (Product Data)
  • Moligand™: Our Moligand line comprises small-molecule library members suitable for discovery screening, SAR exploration, and hit validation workflows.
• What Moligand™ implies (general description; not item-specific specs)
  • Identity and purity are controlled to enable reproducible screening; typical documentation includes CoA with structure identifiers (where permitted), purity by HPLC/UPLC, and orthogonal identity (e.g., MS). Exact acceptance criteria for MHY-1685 are Not specified for this item; refer to CoA/Spec Sheet.
  • Packaging is optimized for low-adsorption and minimal moisture exposure; many SKUs are provided as dry films or lyophilized solids for rapid DMSO dissolution.
• Stabilizers/inhibitors
  • None stated for this item. If a stabilizer is present, it will be declared on the CoA/label. Do not assume presence or absence without documentation.
• Batch-specific documentation
  • To support high-throughput use, batch metadata (lot number, packaging format, fill mass or concentration for solution formats) are provided on the label/CoA.
• Fit for purpose
  • While suitable for research screening, Moligand material is not intended for GMP or clinical use. For analytical or synthetic reagent applications requiring specific contaminants/UV cutoff limits, request the CoA; non-listed specifications should be considered Not specified for this item.

If you have platform-specific constraints (e.g., LC-MS clean rooms, photo-lability limits), please contact us with your requirements for a suitability assessment.

Reaction & Applications

This SKU is positioned as a Moligand™ small-molecule library member for discovery screening rather than as a synthetic reagent.

• Primary use domain (Product positioning)
  • Research screening and ligand discovery in biochemical or biophysical assays. No manufacturer application text is provided beyond the product name; specific biological targets or modalities are Not specified for this item.
• Laboratory applications (general, non-clinical)
  • Preparation of concentration–response curves, assay method development (solubility/aggregation controls), and orthogonal confirmation runs (e.g., thermal shift vs. binding assays) in early-stage research settings.
• Not typical for
  • Serving as a stoichiometric reagent, catalyst, or solvent in preparative organic synthesis, due to absent reactivity specifications.
• Practical tips
  • Establish a reference handling protocol: stock concentration, aliquot size to avoid freeze–thaw, and plate-mapping metadata.
  • Include appropriate vehicle controls (matching DMSO %), and screen for assay interference (autofluorescence, redox activity) with counterscreens where applicable.

If you intend to repurpose this material for chemical synthesis, note that functional groups, reactivity, and stability are Not specified; obtain structure and reactivity data from the CoA or your internal characterization before planning transformations.

Reaction Conditions

Reaction condition guidance is not applicable: MHY-1685 is supplied as a screening library compound with no disclosed functional groups, and it is not positioned for use as a reagent or catalyst.

• Item-specific conditions
  • Not specified for this item; refer to CoA/Spec Sheet if you intend to employ it in a chemical transformation.
• Assay preparation conditions (general, non-reaction)
  • Stock preparation: Typically in anhydrous DMSO at 10–50 mM (verify solubility empirically).
  • Working solutions: Dilute into assay buffer with vigorous mixing; maintain final DMSO within validated limits (commonly 0.1–1% v/v).
  • Stability: Keep solutions cold and protected from light until data on photolability or hydrolytic stability are available.

Safety & Handling

• GHS/Hazard information (Product Data)
  • Signal word: Not specified for this item; refer to SDS.
  • Hazard statements (H-phrases): Not specified for this item; refer to SDS.
  • GHS classification/pictograms: Not specified for this item; refer to SDS.
• Storage and shipping (Product Data)
  • Store at −80 °C. Shipped on dry ice packs + cold packs.
• General laboratory precautions (best practice; defer to SDS for authority)
  • Use in a chemical fume hood. Avoid inhalation of powders/aerosols and contact with skin/eyes.
  • Recommended PPE: lab coat, safety glasses or face shield, and appropriate chemically resistant gloves (e.g., nitrile). Change gloves frequently when handling DMSO solutions due to enhanced dermal transport.
  • Avoid incompatible materials until specific data are available; as a precaution, segregate from strong oxidizers, strong acids/bases, and reactive reducing agents.
  • For unknown dust toxicity, handle solids gently to minimize airborne particulates; consider weighing in a balance enclosure.
• First-aid overview (consult SDS and institutional protocols)
  • Inhalation: Move to fresh air; seek medical attention if symptoms persist.
  • Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; obtain medical advice.
  • Ingestion: Rinse mouth; do not induce vomiting unless directed by medical personnel.
• Waste and spill response
  • Absorb small spills with inert material; collect as hazardous waste. Dispose according to local regulations, noting potential DMSO content when applicable.

Always consult the product-specific SDS for authoritative hazard, exposure limit, and incompatibility information.

Solvent Selection

Given the item is a small-molecule screening ligand with limited published solubility data, solvent selection should prioritize broad compatibility with biochemical and cell-free assay systems.

• Primary stock solvent (general best practice)
  • DMSO (anhydrous): First-line choice for preparing 10–50 mM stocks due to wide solubilizing power and assay compatibility at 0.1–1% v/v.
• Secondary/alternative solvents (general)
  • DMF or NMP: Useful for highly crystalline/hydrogen-bonding solutes; evaluate assay tolerance.
  • Ethanol or isopropanol: For assays permitting alcohol co-solvents; often compatible up to ~1% v/v.
  • Aqueous buffers: Only if the compound is sufficiently polar/ionizable; unknown for this item.
• Practical workflow
  • Assess solubility by small-scale titration (e.g., add DMSO incrementally while vortexing/sonicating). If undissolved material persists, warm gently (≤40 °C) briefly and re-evaluate after cooling to ambient.
  • For aqueous dosing, pre-dilute DMSO stock into buffer with vigorous mixing to avoid local supersaturation; keep final DMSO fraction within assay tolerances.
• Adsorption/precipitation checks
  • Inspect for precipitation after dilution into assay medium over the experiment window; consider using low-bind plastics or glass vials to minimize surface losses.
• When to choose alternatives
  • If your screening platform restricts DMSO, consider ethanol or DMF within validated limits. If neither is allowed, investigate cyclodextrin inclusion or surfactant-free microemulsions, subject to assay validation.

Item-specific solvent preferences, pKa, or logP are Not specified for this item; consult the CoA or perform an internal solubility assessment.

Storage & Reconstitution

• Item-specific storage (Product Data)
  • Store at −80 °C.
  • Shipped on dry ice packs + cold packs to preserve frozen integrity during transit.
• Reconstitution (general guidance for small molecules; not item-specific specs)
  • Preferred solvent: DMSO (anhydrous). Begin with modest volume and titrate to achieve complete dissolution; target 10–50 mM stocks if solubility allows.
  • Filtration: If particulate remains after dissolution, allow to settle and transfer supernatant, or filter through a compatible 0.2 µm PTFE membrane. Be mindful of adsorption losses.
  • Aliquoting: Prepare single-use aliquots in low-bind tubes/plates to avoid repeated freeze–thaw cycles.
• Storage of solutions (general)
  • DMSO stocks: Store at −80 °C, protected from light and moisture. Stability is compound-dependent and Not specified for this item; verify by periodic LC–MS/UPLC checks.
  • Thawing: Thaw on ice immediately before use. Mix thoroughly; avoid repeated warming.
• Solid state considerations
  • If supplied as a dry film or powder, equilibrate the container to room temperature in a desiccator before opening to prevent condensation. Reseal promptly under dry inert gas if available.

For definitive stability and reconstitution instructions specific to MHY-1685, consult the batch CoA and SDS; where information is absent, perform small-scale pilot tests to confirm suitability for your workflow.

Structure & Identity

Brief overview: MHY-1685 is offered as a Moligand-grade small-molecule library member for research screening workflows. Limited structure metadata are provided for this catalog entry.

• Item-specific identifiers (Product Data)
  • SKU: M1496928
  • Product name: MHY-1685
  • CAS: 27406-31-1
  • PubChem CID: 5292673
  • Grade: Moligand™
  • Research use: For research use only
• Structure descriptors
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Structural features (general note)
  • A detailed functional-group description, ring system annotation, and stereochemical information are not provided in the current Product Data. If you require these for screening panel selection, please request the technical package or consult the Certificate of Analysis (CoA) associated with your batch.
• 2D structure (descriptive)
  • Not available in the Product Data. When available, we provide a line notation (SMILES) and/or structure image for cheminformatics ingestion. Contact support for structure-enabled selection files (SDF, SMILES) if permitted for this SKU.

Synthetic Utility

This SKU is not positioned as a synthetic reagent and lacks disclosed functional-group information.

• Item-specific reactivity or transformations
  • Not specified for this item; refer to CoA/Spec Sheet if you plan to use it in chemical synthesis.
• General guidance
  • Before attempting derivatization, confirm structure and purity by orthogonal methods (NMR, LC–MS, HRMS) and assess stability in chosen solvents. Without known functional groups, standard retrosynthetic planning cannot be provided.
• When synthesis-relevant
  • If MHY-1685 is part of a SAR campaign, parallel synthesis of analogs should be based on the verified structure and may require protecting-group strategies, coupling choices, and specific chemoselectivity controls that are not inferable from current Product Data.

Target Specificity

• Target, pathway, or enzyme class
  • Not specified for this item in the Product Data.
• Species reactivity, selectivity metrics, or binding constants
  • Not provided. Do not infer pharmacology or bioactivity from catalog inclusion alone.

If you have internal data linking MHY-1685 to a target, we recommend documenting assay context (format, readout, cofactors), control compounds, and counterscreens to substantiate specificity claims. Aladdin Scientific provides this SKU strictly for research use without target annotations.

Frequently Asked Questions

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.